ProKidneyPROK
PROK
About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Employees: 204
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 18
2.74% less ownership
Funds ownership: 39.79% [Q4 2024] → 37.05% (-2.74%) [Q1 2025]
5% less funds holding
Funds holding: 74 [Q4 2024] → 70 (-4) [Q1 2025]
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
33% less call options, than puts
Call options by funds: $4K | Put options by funds: $6K
51% less capital invested
Capital invested by funds: $86.1M [Q4 2024] → $42M (-$44M) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
78%
downside
Avg. target
$5
10%
upside
High target
$9
98%
upside
2 analyst ratings
1 positive
50%
0 neutral
0%
1 negative
50%
Citigroup Yigal Nochomovitz | 98%upside $9 | Buy Maintained | 9 Jul 2025 |
B of A Securities Jason Gerberry | 78%downside $1 | Underperform Downgraded | 30 Jun 2025 |
Financial journalist opinion
Based on 10 articles about PROK published over the past 30 days
Positive
Zacks Investment Research
2 days ago
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
Positive
Yahoo Finance
2 days ago
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on August 1st and that date will not change.
Positive
Forbes
2 days ago
ProKidney: What's Happening With PROK Stock?
ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from chronic kidney disease (CKD) and diabetes. The study indicated considerable enhancements in kidney function:
Neutral
GlobeNewsWire
2 days ago
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:
Positive
The Motley Fool
3 days ago
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
ProKidney (PROK 513.36%) shares closed at $3.73, rising 515% today while the S&P 500 fell 0.1% and the Dow Jones Industrial Average dropped 0.4%.
Positive
Market Watch
3 days ago
ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying
The stock of the day on Tuesday was ProKidney Corp.'s, as it was both the biggest gainer and the most actively traded on major U.S. exchanges, after the biotechnology company's diabetes treatment produced positive results in a mid-stage trial.
Neutral
Benzinga
3 days ago
Gold Falls 1%; ProKidney Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.
Positive
Benzinga
3 days ago
Why Is Penny Stock ProKidney Trading Higher On Tuesday?
ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.
Neutral
GlobeNewsWire
3 days ago
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
WINSTON-SALEM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial evaluating rilparencel in patients with CKD and diabetes. Rilparencel is an autologous cellular therapy that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food & Drug Administration (FDA) and is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy's potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
Neutral
GlobeNewsWire
1 week ago
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A common stock of ProKidney Corp., a Delaware corporation and (ii) each Class B ordinary share automatically converted into one share of Class B common stock of ProKidney. ProKidney common stock will begin trading on July 2, 2025, and the Company's trading symbol on the Nasdaq Stock Market will remain unchanged as "PROK." The Company's CUSIP number relating to its Class A common stock changed to 74291D 104. The Company does not anticipate any impact to day-to-day business operations as a result of the domestication.
Charts implemented using Lightweight Charts™